Cardiovascular surgical and interventional procedures are performed to treat condition causing inadequate blood flow and supply of oxygen and nutrients to organs and tissues of the body. These conditions include the obstruction or deformation of arterial and venous pathways, distortion in the electrical conducting and pacing activity of the heart, and impaired pumping function of the heart muscle, or some combination of circulatory, cardiac rhythm, and myocardial disorders. Specifically, these procedures are:
- Coronary artery bypass graft (CABG) surgery;
- Coronary angioplasty and stenting;
- Lower extremity arterial bypass surgery;
- Percutaneous transluminal angioplasty (PTA) with and without bare metal and drug-eluting stenting;
- Peripheral drug-coated balloon angioplasty;
- Peripheral atherectomy;
- Surgical and endovascular aortic aneurysm repair;
- Vena cava filter placement
- Endovenous ablation;
- Mechanical venous thrombectomy;
- Venous angioplasty and stenting;
- Carotid endarterectomy;
- Carotid artery stenting;
- Cerebral thrombectomy;
- Cerebral aneurysm and AVM surgical clipping;
- Cerebral aneurysm and AVM coiling & flow diversion;
- Left Atrial Appendage closure;
- Heart valve repair and replacement surgery;
- Transcatheter valve repair and replacement;
- Congenital heart defect repair;
- Percutaneous and surgical placement of temporary and permanent mechanical cardiac support devices;
- Pacemaker implantation;
- Implantable cardioverter defibrillator placement;
- Cardiac resynchronization therapy device placement;
- Standard SVT & VT ablation; and
- Transcatheter AFib ablation
For 2016 to 2022, the total worldwide volume of these cardiovascular procedures is forecast to expand on average by 3.7% per year to over 18.73 million corresponding surgeries and transcatheter interventions in the year 2022. The largest absolute gains can be expected in peripheral arterial interventions (thanks to explosive expansion in utilization of drug-coated balloons in all market geographies), followed by coronary revascularization (supported by continued strong growth in Chinese and Indian PCI utilization) and endovascular venous interventions (driven by grossly underserved patient caseloads within the same Chinese and Indian market geography).
Venous indications are also expected to register the fastest (5.1%) relative procedural growth, followed by peripheral revascularization (with 4.0% average annual advances) and aortic aneurysm repair (projected to show a 3.6% average annual expansion).
Source: MedMarket Diligence, LLC; “Global Dynamics of Surgical and Interventional Cardiovascular Procedures, 2015-2022,” (Report #C500).
Geographically, Asian-Pacific (APAC) market geography accounts for slightly larger share of the global CVD procedure volume than the U.S. (29.5% vs 29,3% of the total), followed by the Largest Western European states (with 23.9%) and ROW geographies (with 17.3%). Because of the faster growth in all covered categories of CVD procedures, the share of APAC can be expected to increase to 33.5% of the total by the year 2022, mostly at the expense of the U.S. and Western Europe.
However, in relative per capita terms, covered APAC territories (e.g., China and India) are continuing to lag far behind developed Western states in utilization rates of therapeutic CVD interventions with roughly 1.57 procedures per million of population performed in 2015 for APAC region versus about 13.4 and 12.3 CVD interventions done per million of population in the U.S. and largest Western European countries.
Source: MedMarket Diligence, LLC; “Global Dynamics of Surgical and Interventional Cardiovascular Procedures, 2015-2022,” (Report #C500).
Global Cardiovascular Procedures report #C500 details the current and projected surgical and interventional therapeutic procedures commonly used in the management of acute and chronic conditions affecting myocardium and vascular system.
